![Eelco Ebbers](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Oorsprong van het eerstegraads netwerk van Eelco Ebbers
Entiteit | Type entiteit | Industrie | |
---|---|---|---|
Symeres BV
![]() Symeres BV Pharmaceuticals: OtherHealth Technology Symeres provides molecule contract research, discovery, development and manufacturing services. The firm offers discovery chemistry, medicinal chemistry, early process research and GMP production services. The company is headquartered in Groningen, the Netherlands.
4
| Holding Company | Pharmaceuticals: Other | 4 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Eelco Ebbers via zijn persoonlijke netwerk
Onderneming | Sector | Gelieerde personen | Hoofdpost |
---|---|---|---|
Parcom Capital Management BV
![]() Parcom Capital Management BV Investment ManagersFinance Parcom Capital Management BV is an independent private equity firm founded in 1982. Parcom Capital Management BV is headquartered in Amsterdam. | Investment Managers | Private Equity Analyst | |
Roslin Cell Therapies Ltd.
![]() Roslin Cell Therapies Ltd. BiotechnologyHealth Technology Roslin Cell Therapies Ltd. is a leading contract development and manufacturing services organization focused on advanced cell and gene therapies. The company was established in 2006 and is based in Edinburgh, UK. and has subsidiaries in the United States. Roslin Cell Therapies has a remarkable heritage in the field, having been among the first in the world to produce clinical-grade human pluripotent stem cells and advancing the first CRISPR edited stem cell-based therapy for a major disease to marketing authorization. The British company provides innovative process and analytical development, CGMP clinical and commercial manufacturing for a range of cell types, and CGMP iPSC cell line development, gene editing, and differentiation. With tailored CDMO solutions, Roslin Cell Therapies enables partners to efficiently progress from development to commercialization and deliver life-saving cell and gene therapies worldwide. Peter Alistair Coleman has been the CEO of the company since 2022. | Biotechnology | Director/Board Member | |
InnoCore Technologies BV
![]() InnoCore Technologies BV Pharmaceuticals: MajorHealth Technology InnoCore Technologies BV develops drug delivery technologies. It serves the pharmaceutical and medical device industry by developing and manufacturing innovative drug delivery systems that enhance their products. The company was founded by Theodorus Adrianus Cornelius Flipsen and Rob Steendam in 2004 and is headquartered in Groningen, the Netherlands. | Pharmaceuticals: Major | Director/Board Member | |
Stanford Graduate School of Business | College/University | Masters Business Admin | |
Varmx BV
![]() Varmx BV BiotechnologyHealth Technology VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018. | Biotechnology | Chief Executive Officer | |
CiMaas BV
![]() CiMaas BV BiotechnologyHealth Technology CiMaas BV develops cellular immunotherapy for cancer. Its products include cancer vaccine using the patient's own immune cells and the production of donor natural killer cells. The company was founded by Gerard M.J. Bos and Dilfred T.V. Germeraad and is headquartered in Maastricht, the Netherlands. | Biotechnology | Director/Board Member | |
VectorY BV
![]() VectorY BV Miscellaneous Commercial ServicesCommercial Services VectorY BV is a biotech company based in Amsterdam, Netherlands, that is dedicated to developing transformative medicines for people with neurodegenerative diseases such as ALS, Huntington's, and Parkinson's. VectorY's platform combines the promise of precise therapeutic antibodies with one-time AAV-based delivery to the CNS, enabling long-lasting CNS treatment after a single administration using cutting-edge antibody, AAV, and manufacturing technologies. The Dutch company's unique in-house expertise in antibodies, AAV vectors, protein degradation, manufacturing, and neuroscience drives the rapid development of much-needed disease-modifying therapies for neurodegenerative diseases. The company was founded by Sander J. van Deventer and Pavlina Konstantinova, with Sander J. van Deventer serving as the CEO since incorporation. | Miscellaneous Commercial Services | Chief Executive Officer | |
ALPHA TEKNOVA, INC. | Pharmaceuticals: Major | Director/Board Member | |
Biogeneration Management BV
![]() Biogeneration Management BV Investment ManagersFinance Biogeneration Management is a venture capital firm, a subsidiary of BioGeneration Holding BV and was founded in 2006. Biogeneration management is headquartered in Naarden. | Investment Managers | Private Equity Investor | |
Alliance for Regenerative Medicine
![]() Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field. | Medical/Nursing Services | Director/Board Member | |
PAION AG | Pharmaceuticals: Major | Chief Executive Officer | |
Gilde Healthcare Partners BV
![]() Gilde Healthcare Partners BV Investment ManagersFinance Gilde Healthcare Partners BV is a Private Equity/Venture Capital firm, a subsidiary of Gilde Healthcare Holding BV founded in 1999 by Pieter van der Meer and Edwin William de Graaf. Gilde Healthcare Partners BV is headquartered in Utrecht with additional office in Cambridge. | Investment Managers | Private Equity Investor | |
McKinsey & Co., Inc.
![]() McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Genzyme Therapeutics Ltd.
![]() Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | Pharmaceuticals: Major | Corporate Officer/Principal | |
MediService AG
![]() MediService AG Drugstore ChainsRetail Trade MediService AG is a mail service pharmacy. The company is headquartered in Zuchwil, Switzerland. | Drugstore Chains | President | |
University of Amsterdam | College/University | Graduate Degree | |
PharmaCell BV
![]() PharmaCell BV BiotechnologyHealth Technology PharmaCell BV manufactures cell therapy and regenerative medicine. The firm engages in human cell line development and manufacturing of bio pharmaceuticals. Its services include process research and development, project management, incoming logistics, incoming goods, manufacturing auto logous and allogeneic products, quality control, final formulation, release and outgoing logistics. The company was founded by René Lardenoije and Jan Thio in 2005 and is headquartered in Maastricht, the Netherlands. | Biotechnology | Chief Executive Officer | |
INSEAD | College/University | Masters Business Admin | |
Erasmus University Rotterdam | College/University | Graduate Degree | |
University of Bocconi | College/University | Undergraduate Degree | |
Ice Lake Capital Management BV
![]() Ice Lake Capital Management BV Investment ManagersFinance Ice Lake Capital Management BV (IceLake Capital) is a private equity firm founded in 2018 by Bastiaan Hagenouw, Matteo Racca and Vincent Lüning. The firm is headquartered in Amsterdam, the Netherlands. | Investment Managers | Founder | |
Syncom BV
![]() Syncom BV Miscellaneous Commercial ServicesCommercial Services Syncom BV is a contract research organization that specializes in all aspects of organic synthesis. Syncom focuses on synthetic chemistry support for mainly medicinal chemistry and chemical development groups. Areas of expertise include asymmetric synthesis, vitamin D and steroid syntheses and heterocyclic chemistry. Dutch resolution is a unique technology used for resolution of racemates by means of diastereomeric salt formation. Chirality in general is specialty of Syncom. About 90% of te current work is done for the pharmaceutical industry and the other 10% for companies interested in materials including organic semiconductors and film components. Syncom is privately owned and was incorporated in 1988. | Miscellaneous Commercial Services | Chief Operating Officer |
Statistieken
Internationaal
Nederland | 14 |
Verenigde Staten | 5 |
Verenigd Koninkrijk | 3 |
Duitsland | 2 |
Zwitserland | 2 |
Sectoraal
Health Technology | 10 |
Consumer Services | 6 |
Finance | 5 |
Commercial Services | 4 |
Health Services | 2 |
Operationeel
Director/Board Member | 7 |
Chief Executive Officer | 4 |
Private Equity Investor | 3 |
Chief Operating Officer | 3 |
Corporate Officer/Principal | 3 |
Sterkste connecties
Insiders | |
---|---|
Alexander Vos | 17 |
Matteo Racca | 7 |
Robert Hof | 2 |
Mark Verhaar | 1 |
- Beurs
- Insiders
- Eelco Ebbers
- Bedrijfsconnecties